Terms: = Ovarian cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
505 results:
1. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
Li H; Peng Z; Zhu J; Zhao W; Huang Y; An R; Zheng H; Qu P; Wang L; Zhou Q; Wang D; Lou G; Wang J; Wang K; Kong B; Xie X; Yin R; Low J; Rozita AM; Sen LC; Meng YC; Kiong KS; Liu J; Liang Z; Lv W; Zhu Y; Hu W; Sun W; Su J; Wang Q; Zang R; Ma D; Gao Q
BMC Med; 2024 May; 22(1):199. PubMed ID: 38755585
[TBL] [Abstract] [Full Text] [Related]
2. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; BacquƩ E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract] [Full Text] [Related]
3. EMP1 correlated with cancer progression and immune characteristics in pan-cancer and ovarian cancer.
Zhang J; Yang J; Li X; Mao L; Zhang Y; Liu Y; Bao Y
Mol Genet Genomics; 2024 May; 299(1):51. PubMed ID: 38743077
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of PD-1/pd-l1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
Chen Y; Liu X; Hu Y; Xia L
Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
[TBL] [Abstract] [Full Text] [Related]
5. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
[TBL] [Abstract] [Full Text] [Related]
6. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
7. Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Tuninetti V; Virano E; Salutari V; Ricotti A; Pisano C; Ducceschi M; Turitto G; Scandurra G; Petrella MC; Forestieri V; Rizzetto M; Mammoliti S; Artioli G; Cioffi R; Borsotti L; Bellero M; Rognone C; Carbone V; Ferrandina G; Mantiero M; Azzolina C; Geninatti E; Pignata S; Valabrega G
Eur J Cancer; 2024 May; 203():114039. PubMed ID: 38598922
[TBL] [Abstract] [Full Text] [Related]
8. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
9. Ginger inhibits the invasion of ovarian cancer cells SKOV3 through CLDN7, CLDN11 and cd274 m6A methylation modifications.
Zhang X; Zhang H; Zhu L; Xia L
BMC Complement Med Ther; 2024 Apr; 24(1):145. PubMed ID: 38575994
[TBL] [Abstract] [Full Text] [Related]
10. Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade.
Nie H; Saini P; Miyamoto T; Liao L; Zielinski RJ; Liu H; Zhou W; Wang C; Murphy B; Towers M; Yang T; Qi Y; Kannan T; Kossenkov A; Tateno H; Claiborne DT; Zhang N; Abdel-Mohsen M; Zhang R
Nat Commun; 2024 Apr; 15(1):2853. PubMed ID: 38565883
[TBL] [Abstract] [Full Text] [Related]
11. Associations of PD-1 and pd-l1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
12. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for ovarian cancer.
Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
[No Abstract] [Full Text] [Related]
13. Targeting Tryptophan Catabolism in ovarian cancer to Attenuate Macrophage Infiltration and pd-l1 Expression.
Crump LS; Floyd JL; Kuo LW; Post MD; Bickerdike M; O'Neill K; Sompel K; Jordan KR; Corr BR; Marjon N; Woodruff ER; Richer JK; Bitler BG
Cancer Res Commun; 2024 Mar; 4(3):822-833. PubMed ID: 38451784
[TBL] [Abstract] [Full Text] [Related]
14. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract] [Full Text] [Related]
15. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
16. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-pd-l1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
Mutch D; Voulgari A; Chen XM; Bradley WH; Oaknin A; Perez Fidalgo JA; Montosa FG; Herraez AC; Holloway RW; Powell MA; Nowicka M; Schaefer G; Merchant M; Yan Y
Cancer; 2024 Jun; 130(11):1940-1951. PubMed ID: 38288862
[TBL] [Abstract] [Full Text] [Related]
17. CD133, CD47, and pd-l1 Expression in ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study.
Masadah R; Ikram D; Riadi R; Tangdiung Y; Nelwan BJ; Ghaznawie M; Rauf S; Faruk M
Asian Pac J Cancer Prev; 2024 Jan; 25(1):249-255. PubMed ID: 38285791
[TBL] [Abstract] [Full Text] [Related]
18. Construction and validation of molecular subtype and signature of immune cell-related telomeric genes and prediction of prognosis and immunotherapy efficacy in ovarian cancer patients.
Ling L; Li B; Wu H; Zhang K; Li S; Ke B; Zhu Z; Liu T; Liu P; Zhang B
J Gene Med; 2024 Jan; 26(1):e3606. PubMed ID: 38282157
[TBL] [Abstract] [Full Text] [Related]
19. Uterine Tumors Resembling ovarian Sex Cord Tumors (UTROSCTs): A Scoping Review of 511 Cases, Including 2 New Cases.
Watrowski R; Palumbo M; Guerra S; Gallo A; Zizolfi B; Giampaolino P; Bifulco G; Di Spiezio Sardo A; De Angelis MC
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38276058
[TBL] [Abstract] [Full Text] [Related]
20. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
Kim SI; Joung JG; Kim YN; Park J; Park E; Kim JW; Lee S; Lee JB; Kim S; Choi CH; Kim HS; Lim J; Chung J; Kim BG; Lee JY
Gynecol Oncol; 2024 Mar; 182():7-14. PubMed ID: 38246047
[TBL] [Abstract] [Full Text] [Related]
[Next]